ich hör immer "this biotechnology company changing the world" und "With fast-track designations, a robust clinical pipeline, and cutting edge science" usw.usw. ,ist da was dran ? Ich werde versuchen zu berichten ...
MFG
Chali
MFG
Chali
Top-News
TapImmune, Inc. (TPIV)
Beiträge: 21
Zugriffe: 5.274 / Heute: 1
Zugriffe: 5.274 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +43,05%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +38,39%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +35,72%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +35,02%
SPDR MSCI World Industrials UCITS ETF
Perf. 12M: +26,59%
An Explosive 2017 Pipeline
The FDA grants orphan designation to a new drug when the need is so great and the available treatment options so abysmal that the medical community is desperately looking for new alternatives.
Two of TapImmune's (NASDAQ: TPIV) six clinical trials have been given such a designation. Their pipeline is full of collaborators, but these specific trails are in partnership with AstraZeneca and Memorial Sloan Kettering Cancer Center - two absolute Cancer Research powerhouse instutions.
They’re also currently enrolling 280 patients in a Phase II study in collaboration with the Mayo Clinic and partially funded with a $17M non-dilutive grant from the department of defense for Triple-Negative Breast cancer.
The FDA grants orphan designation to a new drug when the need is so great and the available treatment options so abysmal that the medical community is desperately looking for new alternatives.
Two of TapImmune's (NASDAQ: TPIV) six clinical trials have been given such a designation. Their pipeline is full of collaborators, but these specific trails are in partnership with AstraZeneca and Memorial Sloan Kettering Cancer Center - two absolute Cancer Research powerhouse instutions.
They’re also currently enrolling 280 patients in a Phase II study in collaboration with the Mayo Clinic and partially funded with a $17M non-dilutive grant from the department of defense for Triple-Negative Breast cancer.
TapImmune's (NASDAQ: TPIV) cancer immunotherapy technology platform combines unique and proprietary sets of peptide antigens designed to elicit both killer T-cell (CD8) and helper T-cell (CD4) immune responses against well-characterized molecular targets that correlate with disease prognosis.
The company’s T-cell cancer vaccines are directed against specific surface proteins present on the majority of target tumor cells. They are comprised of naturally processed antigens derived from human immune responses that are recognized by more than 80% of the population, and they include a mix of antigens that are displayed by MHC class I and II molecules. TapImmune is therefore able to direct a uniquely robust and durable anti-tumor immune response across a wider patient population.
The company’s T-cell cancer vaccines are directed against specific surface proteins present on the majority of target tumor cells. They are comprised of naturally processed antigens derived from human immune responses that are recognized by more than 80% of the population, and they include a mix of antigens that are displayed by MHC class I and II molecules. TapImmune is therefore able to direct a uniquely robust and durable anti-tumor immune response across a wider patient population.
OncoMed Pharmaceuticals, Inc. (OMED) , 150 mio
Clovis Oncology, Inc. (CLVS) , 4 MRD
Pharma Mar, S.A. (PHM.MC) , 800 mio
ZIOPHARM Oncology, Inc. (ZIOP) , 800 mio
OncoSec Medical Incorporated (ONCS) , 20 mio
Kura Oncology, Inc. (KURA) , 200 mio
Loxo Oncology, Inc. (LOXO) , 2 MRD
Clovis Oncology, Inc. (CLVS) , 4 MRD
Pharma Mar, S.A. (PHM.MC) , 800 mio
ZIOPHARM Oncology, Inc. (ZIOP) , 800 mio
OncoSec Medical Incorporated (ONCS) , 20 mio
Kura Oncology, Inc. (KURA) , 200 mio
Loxo Oncology, Inc. (LOXO) , 2 MRD
NET-Cash ~ 0,82$ Ende Juni 17
As of August 2, 2017, the Company had 10,158,993 shares of common stock issued and outstanding.
secfilings.nasdaq.com/...0INC.&FormType=10-Q&View=html
stimme Dir zu.
Aber Wert ist - bei niedrigerem Sharepreis - durchaus interessant.
Aber Wert ist - bei niedrigerem Sharepreis - durchaus interessant.
ja,das mit 10 mio shares und somit 30 mio Mcap stimmt schon,und ich weiss nicht wieso Cobra7 dieses als "zu teuer" bezeichnet ??? Meine Verhleichswerte aus #5 sind jedenfalls alle (mit einer Ausnahme) deutlich teurer ! Und der eigentliche Witz ist,meine Tippgeber,ein US Börsenguru mit namen Bill Matthews,vergleicht Tapimmune mit Amgen im absoluten Frühstadium,aber ich kann das nur so wiedergeben,selber hab ich keinen Schimmer ,ob das hier die nächste Amgen oder die nächste Aeterna Zentaris wird ...... mal sehen .....
MFG+
Chali
MFG+
Chali
welcher Phase befinden sich die Studien denn, hmmm
bei dem Cash, werden noch einige KEs kommen,oder ??
viel zu hoch für PII, da bei Fail. locker -80% drin sind !!!
jaja,schon klar,das weiss ich auch wohl,vielleicht taugt die Aktie ja nix,das kann natürlich sein,aber ich habe noch einen "Plan B",vielleicht tut ihr eurer Meinung da auch kund,die sind mit 20 mio noch günstiger a<ls Tapimmune:
http://www.ariva.de/forum/oncosec-medical-incorporated-oncs-549694
http://www.ariva.de/forum/oncosec-medical-incorporated-oncs-549694
habe soeben aus Übersee erfahren,dass Oncosec warscheinlich auch nix taugt,aber was heisst schon "auch" ? Wir wissen ja noch garniocht,ob Tapimmune taugt oder nicht,hm ?
insiderfinancial.com/...tpiv-has-some-key-catalysts-coming-up
When we last covered TapImmune Inc (NASDAQ:TPIV) back in February, the company was trading for around $4 flat. We highlighted it as one to keep an eye on throughout 2017 based on the fact that it had finally got its ducks lined up and there was some degree of potential to get various catalysts in the hands of markets and to start moving in line with fundamental development.
Fast forward to today and we’ve seen practically nothing from the company that could get markets excited. TapImmune goes for $3.05 and commands a market capitalization of just $32 million. For a company that counts AstraZeneca plc (ADR) (NYSE:AZN) among its commercial collaborators and that has two (soon to be three) mid stage oncology assets in development alongside entities like Memorial Sloan, Mayo Clinic and the Department of Defense, this seems like a crazy undervaluation as compared to peers in a similar (or worse) situation.
Our bull thesis last time rested on this above-described disparity in true and actual valuation.
Now, it seems as though the company has just been sitting on its hands for the last six months; that would explain why we’ve not seen any real updates or press releases as to how things are maturing with regards to the development programs currently underway.
That’s not necessarily true, however.
There are three trials that are really going to drive value for this company over the coming 24 months. These are a phase II investigating TPIV200 in combination with AstraZeneca’s Durvalumab in patients with ovarian cancer; another phase II investigating the same asset in the same indication but in combination with an adjuvant called Leukine and as compared to Leukine alone; and another that’s basically the same as the second (phase II, drug with adjuvant) but in a breast cancer indication.
All are enrolling as we speak, with the first having kicked off in May last year, the second kicking off in January this year and the third kicking off in April.
The problem is, as we see it, that these trials are pretty slow burners. Markets don’t like slow burners and, in the absence of any report-worthy numbers (these are survival studies, meaning it’s tough to gauge efficacy before a certain threshold is reached), the company hasn’t been able to keep markets interested in what’s going on.
That’s to this point, however.
As per this week, a new CEO is in place, Peter L. Hoang, and we think this is a strategic move ahead of the company trying to get some traction in the public markets.
If the trials are slow burners, how is this possible?
Well, the adjuvant/vaccine trial in ovarian cancer isn’t going to complete before 2020 and it’s a blinded study, so we can write that one off as likely having no reportable news for a while.
The other two, however, could be interesting.
The TPIV200/Durvalumab trial is set to complete in May next year. That’s around six months ago, sure, but it’s an open label study and there’s a one-year RECIST marker, meaning many of the 40 patients enrolled will likely already have reached measurement threshold. This means we’ve got the potential for some interim numbers before the top line hits press.
The vaccine/adjuvant study in breast cancer isn’t going to complete before December 2020. However, it’s also open-label and TapImmune has set December 2017 as a primary completion date, meaning there’s a good chance we’ll get some early indication of efficacy in and around this point (so, in around twelve weeks’ time). At this point, the first patients will have been dosed monthly for six months and will be at the first booster dose point – allowing for a key progression measurement. If only a small number have progressed (so, their cancer has gotten worse) then it will imply efficacy and this stock is really going to run.
These trials are funded in part through the collaborations but there’s always a dilution risk at this end of the market so keep that in mind, but it’s about time we started to see some speculative loading and – if the numbers are favorable – it’s only going to be a short time before this stock takes off.
Here are the three protocols:
Trial 1
Trial 2
Trial 3
Check out our previous coverage of TPIV here.
We will be updating our subscribers as soon as we know more. For the latest updates on TPIV, sign up below!
When we last covered TapImmune Inc (NASDAQ:TPIV) back in February, the company was trading for around $4 flat. We highlighted it as one to keep an eye on throughout 2017 based on the fact that it had finally got its ducks lined up and there was some degree of potential to get various catalysts in the hands of markets and to start moving in line with fundamental development.
Fast forward to today and we’ve seen practically nothing from the company that could get markets excited. TapImmune goes for $3.05 and commands a market capitalization of just $32 million. For a company that counts AstraZeneca plc (ADR) (NYSE:AZN) among its commercial collaborators and that has two (soon to be three) mid stage oncology assets in development alongside entities like Memorial Sloan, Mayo Clinic and the Department of Defense, this seems like a crazy undervaluation as compared to peers in a similar (or worse) situation.
Our bull thesis last time rested on this above-described disparity in true and actual valuation.
Now, it seems as though the company has just been sitting on its hands for the last six months; that would explain why we’ve not seen any real updates or press releases as to how things are maturing with regards to the development programs currently underway.
That’s not necessarily true, however.
There are three trials that are really going to drive value for this company over the coming 24 months. These are a phase II investigating TPIV200 in combination with AstraZeneca’s Durvalumab in patients with ovarian cancer; another phase II investigating the same asset in the same indication but in combination with an adjuvant called Leukine and as compared to Leukine alone; and another that’s basically the same as the second (phase II, drug with adjuvant) but in a breast cancer indication.
All are enrolling as we speak, with the first having kicked off in May last year, the second kicking off in January this year and the third kicking off in April.
The problem is, as we see it, that these trials are pretty slow burners. Markets don’t like slow burners and, in the absence of any report-worthy numbers (these are survival studies, meaning it’s tough to gauge efficacy before a certain threshold is reached), the company hasn’t been able to keep markets interested in what’s going on.
That’s to this point, however.
As per this week, a new CEO is in place, Peter L. Hoang, and we think this is a strategic move ahead of the company trying to get some traction in the public markets.
If the trials are slow burners, how is this possible?
Well, the adjuvant/vaccine trial in ovarian cancer isn’t going to complete before 2020 and it’s a blinded study, so we can write that one off as likely having no reportable news for a while.
The other two, however, could be interesting.
The TPIV200/Durvalumab trial is set to complete in May next year. That’s around six months ago, sure, but it’s an open label study and there’s a one-year RECIST marker, meaning many of the 40 patients enrolled will likely already have reached measurement threshold. This means we’ve got the potential for some interim numbers before the top line hits press.
The vaccine/adjuvant study in breast cancer isn’t going to complete before December 2020. However, it’s also open-label and TapImmune has set December 2017 as a primary completion date, meaning there’s a good chance we’ll get some early indication of efficacy in and around this point (so, in around twelve weeks’ time). At this point, the first patients will have been dosed monthly for six months and will be at the first booster dose point – allowing for a key progression measurement. If only a small number have progressed (so, their cancer has gotten worse) then it will imply efficacy and this stock is really going to run.
These trials are funded in part through the collaborations but there’s always a dilution risk at this end of the market so keep that in mind, but it’s about time we started to see some speculative loading and – if the numbers are favorable – it’s only going to be a short time before this stock takes off.
Here are the three protocols:
Trial 1
Trial 2
Trial 3
Check out our previous coverage of TPIV here.
We will be updating our subscribers as soon as we know more. For the latest updates on TPIV, sign up below!
So jedenfalls scheint der CEO es und einige Spekulanten auf Seeking Alpha
Und den Kick gibt die erste Finanzspritze nach dem Merger via einer Privatplazierung.
Aber 17,5Mio. neue Aktien a' nur 4$ !? Das müsste doch den Kurs erstmal wieder zurückwerfen, oder?
(Verkleinert auf 39%) 
hallo leute,
ich habe das Teil hier aus den Augen verloren,wie heissen die heute ?
MFG
Chali
ich habe das Teil hier aus den Augen verloren,wie heissen die heute ?
MFG
Chali
Neueste Beiträge aus dem TapImmune Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 20 | TapImmune, Inc. (TPIV) | Chalifmann3 | RichyBerlin | 24.04.21 22:58 | ||
| 1 | TapImmune Quartalsbericht | Megas_Polemarch. | Megas_Polemarch. | 04.07.09 10:06 |
